Core Insights - Innovent Biologics announced that the Phase 3 clinical trial of mazdutide met its primary and key secondary endpoints, indicating its efficacy for weight management in Chinese adults with obesity [1][2][3] Clinical Trial Details - The GLORY-2 study involved 462 participants with a mean baseline weight of 94.0 kg and a mean BMI of 34.3 kg/m², randomized to receive either mazdutide 9 mg or placebo over a 60-week period [2] - Participants in the mazdutide group experienced a mean weight reduction of 18.55% at Week 60, compared to 3.02% in the placebo group, with 44.0% achieving a weight reduction of 20% or more [3][4] Secondary Endpoints and Safety - All key secondary endpoints were met, including improvements in waist circumference, blood pressure, and lipid levels, demonstrating the drug's superiority over placebo [4][5] - The treatment showed favorable tolerability, with a low discontinuation rate due to adverse events (2.9% in the mazdutide group) [6] Expert Commentary - Experts highlighted the significance of mazdutide in addressing obesity, particularly in a country with a high prevalence of obesity and related cardiometabolic diseases [7] - The drug is positioned as a viable alternative to metabolic surgery, with evidence supporting its effectiveness in weight management [7][8] Future Plans and Recognition - Innovent plans to submit a new drug application for mazdutide to the NMPA and is exploring further therapeutic potentials for the drug [8][10] - Mazdutide has received recognition in top-tier journals and was listed among the "Top 10 Most Anticipated Drug Launches of 2025" [8][9] Company Overview - Innovent Biologics, founded in 2011, focuses on developing high-quality biopharmaceuticals for various diseases and has launched 16 products to date [17]
Mazdutide 9 mg Achieves Up to 20.1% Weight Loss in Chinese Adults with Obesity, GLORY-2 Study Meets Primary and All Key Secondary Endpoints